-
Anti-cytokine Signatures in Inflammatory Skin Disease
This pilot project intends to examine the utility of a systems medicine approach to identify regulatory networks and their perturbation in psoriasis and atopic dermatitis, and to obtain a comprehensive perspective on disease and disease control by integrating and modelling data across multiple cellular levels and time following specific blockade of single pathophysiological factors through use of licensed biologics during routine care as systems biology challenge. To this end, ultra-deep phenotyping and prospective molecular characterization in short time-intervals and different disease equilibrium states will be carried out in targeted...
-
APACHE Cohort (A Psoriatic Arthritis CoHort)
Psoriatic arthritis (PsA) is a chronic inflammatory rheumatic disease, belonging to the wide spectrum of spondyloarthritis, but with the particularity to be associated with personal psoriasis or familial psoriasis. PsA can be a very disabling disease through progressive and irreversible joint damage. Long-term functional prognosis of patients with PsA is correlated with the presence and severity of the radiographic joint lesions of the disease. However, the proportion of patients who will develop those peripheral joint damages is not yet known and less over the factors which are associated/involved in such an aggressive pattern of the...
-
A Phase 2, Multicenter, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pefcalcitol Ointment, 0.005%, Applied Topically Twice Daily (BID) for 8 Weeks in Adolescent Subjects 12 to < 17 Years of Age With Plaque Psoriasis
A multi-center, open-label study that will evaluate the safety/tolerability and pharmacodynamics as well as the pharmacokinetic profile (sub-population analysis), in 50 evaluable adolescents 12 to < 17 years of age.
-
A Phase II Study to Evaluate Efficacy & Safety of AUR101 in Patients of Moderate-to-Severe Psoriasis
This will be a multicenter, double-blind, double-dummy, placebo controlled, randomized study to evaluate efficacy and safety of AUR101 (RORgamma inhibitor) in patients with moderate-to-severe psoriasis. Approximately 90 patients with chronic moderate-to-severe plaque psoriasis will be randomized to the 2 dose groups of AUR101 and one group of Placebo. The patients will receive the treatment for 12 weeks.
-
A Pilot Study to Explore the Role of Gut Flora in Psoriasis
This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records regarding Psoriasis.
-
APremilast After FumaRic Acid Ester Treatment
Patient treatment preference and treatment satisfaction of physicians and patients comparing fumaric acid ester therapy with subsequent apremilast treatment
-
Apremilast in Combination With Clobetasol Spray for the Treatment of Plaque Psoriasis
Researchers want to find out if giving the drug Apremilast in combination with Clobetasol spray can help people clear their moderate to severe plaque psoriasis quicker than if Apremilast is used by itself.
-
Apremilast in Psoriatic Arthritis in Real-life Clinical Practice in Greece
Following the evidence from the controlled clinical trial setting on the significant clinical benefits of apremilast in the treatment of active PsA, there is a scarcity of real-life evidence on the effectiveness and the beneficial role of apremilast in PsA in routine clinical practice. The present study primarily aims to generate real-world evidence on the impact of apremilast treatment on a broad population of biologic-naïve PsA patients in terms of its clinical effectiveness across the wide spectrum of disease manifestations, as well as its impact on disease burden and HRQoL, in the routine primary care settings of Greece.
-
Apremilast Pregnancy Exposure Registry
The purpose of the Apremilast Pregnancy Exposure Registry is to monitor planned and unplanned pregnancies exposed to apremilast and to evaluate the safety of this medication relative to specified pregnancy outcomes, and to evaluate potential effects of prenatal apremilast exposure on infant health status through one year of age.
-
Apremilast Treatment for Pruritus and Quality of Life in Scalp Psoriasis
A phase 4 multicenter, randomized, placebo-controlled Study evaluating the Effect of Apremilast on Pruritus and Quality of Life of Patients with moderate-to-severe Scalp Psoriasis
21 - 30 of 280 Trials
- Psoriasis
-
- Psoriatic Arthritis
-
- Psoriatic Disease
- Stay Healthy
-
Community
- icon:
Navigation CenterLink text:Get free, personalized guidance and support for psoriasis and psoriatic arthritis. - icon:
Talk PsoriasisLink text:The world’s online support community for those impacted by psoriasis or psoriatic arthritis. - icon:
One to OneLink text:Are you newly diagnosed? Have questions? Connect with someone who’s been through it. - icon:
Our SpotLink text:A new website for parents, kids and teens with psoriasis and psoriatic arthritis!
Stay Informed
- icon:
Health WebcastsLink text:Hear world-class experts provide the latest information on psoriatic disease.
-
- Get Involved
-
- Events and Programs
- icon:
Team NPFLink text:Join a group of everyday people dealing with psoriatic disease by walking, running, cycling and DIY-ing for a cure. - icon:
More than Skin DeepLink text:Outsmart psoriasis and psoriatic arthritis from the inside out at this local event.
-
- Research
-
- NPF Funded Research
- icon:
Victor Henschel BiobankLink text:A collection of biological samples and clinical information used by qualified scientists to advance the field of psoriasis genetics.
-
- Medical Professionals
-
- Stay Up-to-date
- icon:
Journal of Psoriasis and Psoriatic ArthritisLink text:Dedicated to providing practical information and research to those working in psoriatic disease care. - icon:
Continuing EducationLink text:Please join us at one of our educational events designed for health care providers.
-
